About Biophytis S.A. (BPTSY) — Dividend Analysis 2026
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19. It also develops BIO201, an orally administered small molecule for the treatment of retinopathies, including dry age-related macular degeneration, and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Is BPTSY a good dividend investment in 2026?
BPTSY offers a 444.44% forward yield with a 50% payout ratio. Strand Safety Score: 30/100 (High Risk). The 5-year dividend CAGR of 0% is modest — investors should weigh current income against growth alternatives.
BPTSY DRIP calculator — what's the difference?
With DRIP on a $10,000 investment over 10 years, your BPTSY portfolio grows to $228841.98M vs $454.4K without reinvestment. This is the compound interest effect in action.
BPTSY dividend growth history & forecast
BPTSY has grown its dividend by 0% over the last year and 0% annually over 5 years. At this pace, an investor who holds for 10+ years will see their yield on cost grow substantially above the current 444.44%.
Company generates negative FCF ($-9M) — borrowing to pay dividends
Debt Leverage0.0× Debt/EBITDA
0 / 30 pts
0/30
Company not generating EBITDA — debt servicing risk is elevated
Earnings Momentum-0.0B → -0.0B → -0.0B
30 / 30 pts
30/30
Net income grew for 2 consecutive years — strong earnings momentum
OVERALL ASSESSMENT
Dividend sustainability questionable — consider alternative income stocks.
STRAND SCORE
30
/100
Strand Safety Score™ is proprietary to DividendFlow. Inputs: FCF, Debt/EBITDA, Net Income from SEC filings via FMP. Not financial advice. N/A for ETFs, pre-revenue companies, and tickers without income statements.
🌍 BPTSY Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold BPTSY.
Gross yield
444.44%
Tax rate
15.00%
After-tax yield
377.77%
Real yield (−CPI)
374.97%
Account/Country
Tax Rate
After-tax Yield
Real Yield
$10K Annual Income
🇺🇸 Roth IRA / 401k
0%
444.44%
441.64%
$44,444 / yr
🇺🇸 US Taxable (15%) ✓
15%
377.77%
374.97%
$37,777 / yr
🇺🇸 US Taxable (20%)
20%
355.55%
352.75%
$35,555 / yr
🇬🇧 UK ISA
0%
444.44%
441.64%
$44,444 / yr
🇬🇧 UK Taxable
8.75%
405.55%
402.75%
$40,555 / yr
🇨🇦 TFSA
0%
444.44%
441.64%
$44,444 / yr
🇨🇦 CA Taxable
25%
333.33%
330.53%
$33,333 / yr
🇦🇺 Super (pension)
15%
377.77%
374.97%
$37,777 / yr
🇦🇺 AU Taxable
30%
311.11%
308.31%
$31,111 / yr
🇩🇪 DE Taxable
26.375%
327.22%
324.42%
$32,722 / yr
🇫🇷 FR Taxable
30%
311.11%
308.31%
$31,111 / yr
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 BPTSY Income Goal & Break-Even
Dividend Break-Even
1yr
Years for dividends to fully repay your BPTSY investment of $0.45/share (🇺🇸 US Taxable (15%) · 15.00% tax)
$10K invested · 10 Years
Dividends earned (DRIP)
$61981.12M
Lost to inflation (2.8% CPI)
−$2.5K
Real purchasing power gain
$61981.11M
12-month CPI (US BLS via FMP economic-indicators).
How much do I need to invest in BPTSY for:
Shares needed
14,118
Capital required
$6,353
Monthly income
$2,000
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 BPTSY Dividend Payment Schedule
BPTSY pays quarterly — 4 times per year. Next ex-div: TBD.
Jan
Feb
Mar
💰
Apr
May
Jun
💰
Jul
Aug
Sep
💰
Oct
Nov
Dec
💰
10 shares
$4.25 / payment
$17.00 / year after tax
100 shares
$42.50 / payment
$170.00 / year after tax
1,000 shares
$425.00 / payment
$1700.00 / year after tax
📊 BPTSY vs Healthcare Benchmarks
How BPTSY compares to typical Healthcare averages.
Benchmark: Healthcare
Dividend Yield▲+441.64% vs sectorBetter
BPTSY
444.44%
avg
2.80%
5Y Dividend CAGR▼-6.80% vs sectorBelow avg
BPTSY
0.00%
avg
6.80%
Payout Ratio▲-5.00% vs sectorBetter
BPTSY
50.00%
avg
55.00%
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for BPTSY sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ BPTSY Insider Activity
No recent SEC filings reported in the last 90 days.
🔬
Financial Health Scores
Altman Z-Score
-15.76
🔴 Distress Zone — elevated dividend cut risk
Safe: >3.0 · Grey: 1.81–3.0 · Distress: <1.81
Piotroski F-Score
1/9
🔴 Weak fundamentals — dividend safety concern
Strong: 7–9 · Moderate: 4–6 · Weak: 0–3
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
📊 About This Data
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the BPTSY dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →